ARS can also reduce the inflammatory cascade caused by mesangial cell activation by inhibiting the production of cytokines [38] (such as the NF-κB signal transduction pathway) and alleviate the subsequent damage to podocytes and tubules, thus reducing proteinuria. This evidence concerns the gene NFKB1 and Axenfeld-Rieger syndrome.